García-Carmona JA

Group of Clinical and Experimental Pharmacology, Institute for Biomedical Research of Murcia (IMIB), Murcia, Spain.

1 paper · ORCID

ArticleKetamine

Rebuilding the atrophied brain: 6-month nasal esketamine therapy expands key frontal and hippocampal regions and reduces serum neurofilament levels in patients with major depressive disorder. A proof-of-concept study of the depTesk (DEPression treatment with ESKetamine) study.

Rodríguez Lorente A, Campos-Navarro MP, Gil Montoya Á +5